Daratumumab and hyaluronidase-fihj is now indicated as part of a combination therapy for the potentially fatal condition that can develop in patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted...
The FDA approved pertuzumab-dpzb for interchangeable use with pertuzumab. The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) for certain adults with HER2-positive breast cancer. Pertuzumab-dpzb...
The FDA has approved the menin inhibitor ziftomenib for adults with relapsed or refractory acute myeloid leukemias harboring susceptible NPM1 mutations. The U.S. Food and Drug Administration (FDA) has approved the use of the...
The FDA approved daratumumab and hyaluronidase-fihj for adults with smoldering multiple myeloma that has a high risk of progression. The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) as...
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in certain adult and pediatric patients 1 year and older. The U.S. Food and...
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory or recurrent multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin-blmf...
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for use after...
The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after first-line therapy. The U.S. Food and Drug Administration (FDA) has approved lurbinectedin (Zepzelca) in combination...
The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine therapy. The U.S. Food and Drug Administration (FDA) has approved imlunestrant (Inluriyo) for the treatment...
The FDA approved pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for multiple tumor types. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous (under the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More